Athena Athena

X
[{"orgOrder":0,"company":"MediWound","sponsor":"BARDA","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces an Additional $10 Million Award from BARDA","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"MediWound"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"MediWound"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, which is under phase 3 clinical development for the treatment of eschar, in patients with deep partial- and/or full-thickness thermal burns.

            Lead Product(s): Anacaulase-bcdb

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 09, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The supplemental funding will support replenishment of NexoBrid (Anacaulase-bcdb) previously procured for emergency preparedness, the pediatric indication sBLA submission to the U.S.FDA, and enrollment of an additional 50 patients in ongoing expanded access treatment protocol.

            Lead Product(s): Anacaulase-bcdb

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $175.0 million Upfront Cash: Undisclosed

            Deal Type: Funding May 09, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY